Having spent the last five years of my life in Tokyo, I wanted to start this month's Editor's comment by offering my very deepest sympathy to all those who have been affected by the earthquake and tsunami in Japan.
Having spent the last five years of my life in Tokyo, I wanted to start this month's Editor's comment by offering my very deepest sympathy to all those who have been affected by the earthquake and tsunami in Japan.
Rich WhitworthMany of my friends are based in Tokyo where they have been more directly harmed by sensationalist overseas reporting than actual events. Nevertheless, the threat of nuclear fallout has lifted its ugly head and made its impact felt all over the world, fuelling shortages of potassium iodide and subsequent debates over whether stockpiles of emergency medicine are adequate. How well are we prepared for the unexpected?
It was heartening, though, to read that many pharma companies, both Japanese and international, responded so very quickly with support in terms of monetary aid and medical supplies. Repercussions of the earthquake will no doubt last for many years to come, and I sincerely hope that such support will continue where needed when fickle news broadcasters move onto fresh stories and the spotlight shifts from the benevolent.
If you want to read more about pharma's response to the situation in Japan, please check our blog at www.pharmtech.com/Japan
In positive news, I am pleased to announce that this month's issue marks something of an evolution for Pharmaceutical Technology Europe. With a number of new regular columns, and a scientific shift in gear, we hope that PTE now offers an even more detailed insight. We now feature a story by our ingredients specialist Patricia Van Arnum, special reports from around the world, and an article showcasing interesting, surprising and sometimes comical regulatory tales from readers. If you have any stories you wish to share, of course anonymously, please send them to our senior compliance officer at agentinplace@advanstar.com; hopefully, others may learn from your company's GMP mishaps.
As always, and perhaps even more important at this time of change, your feedback is extremely welcome, as is your continued support.
Best wishes,
Rich Whitworth, Editor
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.